Strong results showing clear progress


2022 was a year of further progress for Ipsen, as our successful strategy enabled us to increase momentum toward our goals. Fully focused on specialty care in our three therapeutic areas—Oncology, Rare Disease and Neuroscience—our growth platforms delivered double-digit sales growth.

Ipsen sales

Year-on-year sales

Core operating income

R&D investment

Ownership of Ipsen’s share capital (% of total capital)